Related Experiment Video

Updated: Jun 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Consensus document on continuous subcutaneous insulin infusion (CSII) treatment in paediatrics with type I diabetes]

R Barrio Castellanos1, B García Cuartero, A Gómez Gila

  • 1Hospital Universitario Ramón y Cajal, Madrid, España. rbarrio.hrc@salud.madrid.org

Anales De Pediatria (Barcelona, Spain : 2003)
|April 23, 2010
PubMed

Insights

Continuous subcutaneous insulin infusion is a viable option for children and adolescents with type 1 diabetes. This Spanish Pediatric Endocrinology Society statement outlines practical considerations for its use in pediatric diabetes management.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes in children and adolescents requires effective glucose control strategies.
  • Continuous subcutaneous insulin infusion (CSII) offers a potential advancement in insulin delivery for pediatric patients.
  • The Spanish Pediatric Endocrinology Society (SEEP) developed a position statement to guide CSII implementation.

Framework:

  • Evidence-based review of international consensus on CSII in pediatric type 1 diabetes.
  • Assessment of indications, suitable candidates, feasibility, and limitations of CSII.
  • Development of consensual answers to practical questions regarding CSII for clinicians.

Implementation:

  • Guidelines for the practical application of CSII in pediatric diabetes care.
  • Considerations for patient selection and suitability for CSII therapy.
  • Addressing the feasibility and potential limitations of CSII in children and adolescents.

Implications:

  • Improved glycemic control and quality of life for pediatric patients with type 1 diabetes.
  • Standardized approach to CSII implementation within the Spanish healthcare system.
  • Enhanced clinical decision-making for endocrinologists managing pediatric diabetes.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...